CLDN18.2 is overexpressed in up to 80% of gastrointestinal adenocarcinomas (primary and metastasized)1and 60% pancreatic tumors in addition to other solid cancers. http://www.ganymed-pharmaceuticals.com/pipeline/imab362.html